Effect of VEGF and anti-VEGF compounds on retinal pigment epithelium permeability: An in vitro study

European Journal of Ophthalmology

Volumn 23, Issue 5, 2013, Pages 690-696

  Campa, Claudio ^a,b  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bevacizumab; Pegaptanib; Permeability; Ranibizumab; Retinal pigment epithelium; Vascular endothelial growth factor

Indexed keywords

AMMONIA; DEXTRAN; FLUORESCEIN DEXTRAN; PEGAPTANIB; POLITEF; RANIBIZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN 121; VASCULOTROPIN 165;

APICAL MEMBRANE; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; ION PERMEABILITY; MEMBRANE PERMEABILITY; MOLECULAR WEIGHT; PARACELLULAR PERMEABILITY; PIGMENT CELL; PRIORITY JOURNAL; TRANSEPITHELIAL ELECTRICAL RESISTANCE;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; APTAMERS, NUCLEOTIDE; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; ELECTRIC IMPEDANCE; HUMANS; RETINAL PIGMENT EPITHELIUM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84881503015     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000248     Document Type: Article

References (28)

1. Zinn KM, Marmor MF. The Retinal Pigment Epithelium. Cambridge, MA: Harvard University;1975.
2. Glotin AL, Debacq-Chainiaux F, Brossas JY, et al. Prematurely senescent ARPE-19 cells display features of age-related macular degeneration. Free Radic Biol Med 2008;44:1348-61.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
4. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611.
5. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
6. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat 2002;200:581-97.
7. Adamis AP, Shima DT, Yeo KT, et al. Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells. Biochem Biophys Res Commun 1993;193:631-8.
8. Miura Y, Klettner A, Roider J. VEGF antagonists decrease barrier function of retinal pigment epithelium in vitro: possible participation of intracellular glutathione. Invest Ophthalmol Vis Sci 2010;51:4848-55.
9. Peng S, Adelman R, Rizzolo LJ. Minimal effects of VEGF and anti-VEGF drugs on the permeability or selectivity of RPE tight junctions. Invest Ophthalmol Vis Sci 2010;51:3216-25.
10. Ghassemifar R, Lai CM, Rakoczy PE. VEGF differentially regulates transcription and translation of ZO-1alpha+ and ZO-1alpha- and mediates trans-epithelial resistance in cultured endothelial and epithelial cells. Cell Tissue Res 2006; 323:117-25.
11. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009;20:158-65.
12. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007;18:502-8.
13. Dunn KC, Aotaki-Keen AE, Putkey FR, Hjelmeland LM. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp Eye Res 1996;62:155-69.
14. Pu FR, Williams RL, Markkula TK, Hunt JA. Expression of leukocyte-endothelial cell adhesion molecules on monocyte adhesion to human endothelial cells on plasma treated PET and PTFE in vitro. Biomaterials 2002;23:4705-18.
15. Campochiaro PA, Hackett SF, Conway BP. Retinoic acid promotes density-dependent growth arrest in human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1991;32: 65-72.
16. Yasunari T, Yanagihara N, Komatsu T, et al. Effect of retinoic acid on proliferation and polyamine metabolism in cultured bovine retinal pigment epithelial cells. Ophthalmic Res 1999; 31:24-32.
17. Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev Physiol 1998;60:143-59.
18. Rizzolo LJ. Polarity and the development of the outer bloodretinal barrier. Histopathology 1997;12:1057-67.
19. Bai L, Zhang Z, Zhang H, et al. HIV-1 Tat protein alter the tight junction integrity and function of retinal pigment epithelium: an in vitro study. BMC Infect Dis 2008;8:77.
20. Abe T, Sugano E, Saigo Y, Tamai M. Interleukin-1beta and barrier function of retinal pigment epithelial cells (ARPE-19): aberrant expression of junctional complex molecules. Invest Ophthalmol Vis Sci 2003;44:4097-104.
21. Ablonczy Z, Crosson CE. VEGF modulation of retinal pigment epithelium resistance. Exp Eye Res 2007;85: 762-71.
22. Balda MS, Whitney JA, Flores C, González S, Cereijido M, Matter K. Functional dissociation of paracellular permeability and transepithelial electrical resistance and disruption of the apical-basolateral intramembrane diffusion barrier by expression of a mutant tight junction membrane protein. J Cell Biol 1996;134:1031-49.
23. Claude P. Morphological factors influencing transepithelial permeability: a model for the resistance of the zonula occludens. J Membr Biol 1978;39:219-32.
24. Matter K, Balda MS. Occludin and the functions of tight junctions. Int Rev Cytol 1999;186:117-46.
25. Miyamoto N, de Kozak Y, Normand N, et al. PlGF-1 and VEGFR-1 pathway regulation of the external epithelial hemato-ocular barrier. A model for retinal edema. Ophthalmic Res 2008;40:203-7.
26. Pitkänen L, Ranta VP, Moilanen H, Urtti A. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci 2005;46:641-6.
27. Miura Y, Roider J. Triamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol 2009;247:641-9.
28. Spitzer MS, Yoeruek E, Sierra A, et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837-42.